Completed × Lymphoma, Large B-Cell, Diffuse × Bortezomib × Clear all ImbruVeRCHOP
Phase 1/2 Completed
38 enrolled
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
33 enrolled 14 charts
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Phase NA Completed
23 enrolled 8 charts
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Completed
27 enrolled 13 charts
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Phase 1 Completed
18 enrolled
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase 2 Completed
279 enrolled 28 charts
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Phase 2 Completed
121 enrolled
SGH652
Phase 1 Completed
6 enrolled
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Phase 2 Completed
206 enrolled 18 charts
REMoDL-B
Phase 3 Completed
1,132 enrolled
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase 1 Completed
93 enrolled
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Phase 1 Completed
33 enrolled
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Phase 2 Completed
164 enrolled 15 charts
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
PS-341 in Treating Patients With Hematologic Cancer
Phase 1 Completed
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Phase 1 Completed
69 enrolled
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Phase 1/2 Completed
49 enrolled 8 charts
Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy
Phase 2 Completed
7 enrolled
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
PS-341 in Treating Patients With Advanced Cancer
Phase 1 Completed